New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export AZN’s income statement to Excel — free account
AstraZeneca PLC
AZNHealthcare Drug Manufacturers General
AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024.
- Revenue
- +6.70%
- EPS
- +23.5%
- Free cash flow
- +1.99%
- Total debt
- +1.75%
Quarter to September 2026, against a year earlier
175.60
0.15
+0.09%
Follow AZN
Alert me
Revenue to profit Q3 FY2026, quarter to Sep 30, 2026
Of every $100 of revenue, $24.42 was left as profit. What is an income statement?
| Revenue | 16.2 | 100.0% |
|---|---|---|
| Cost of revenue | −2.9 | −18.2% |
| Gross profit | 13.3 | 81.8% |
| Research & development | −3.9 | −24.0% |
| Selling, general & admin | −5.3 | −32.4% |
| Other operating costs | +0.3 | 1.7% |
| Operating income | 4.4 | 27.1% |
| Other income, net | −0.4 | −2.6% |
| Income tax | −0.8 | −5.2% |
| Other items | +0.8 | 5.2% |
| Net income | 4.0 | 24.4% |
Net margin (right axis)
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Revenue | $15.5B | $15.3B | $15.4B | $16.2B |
| Operating income | $3.0B | $4.2B | $3.2B | $4.4B |
| Net income | $2.6B | $3.9B | $2.8B | $4.0B |
| Net margin (right axis) | 17.0% | 25.6% | 18.2% | 24.4% |
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Revenue |
+8 more quarters Free account |
15,503.00 | 15,288.00 | 15,384.00 | 16,209.00 |
Revenue Growth |
4.11% | 12.51% | 6.41% | 6.70% | |
Cost of Revenue |
3,118.00 | 2,678.00 | 2,523.00 | 2,946.00 | |
Gross Profit |
12,385.00 | 12,610.00 | 12,861.00 | 13,263.00 | |
R&D Expenses |
3,862.00 | 3,492.00 | 4,053.00 | 3,894.00 | |
SG&A Expenses |
5,645.00 | 5,061.00 | 5,796.00 | 5,259.00 | |
Operating Income |
2,978.00 | 4,246.00 | 3,164.00 | 4,387.00 | |
Non-operating Interest Expenses |
472.00 | 393.00 | 435.00 | 477.00 | |
Non-operating Income/Expense |
(349.00) | (332.00) | (365.00) | (429.00) | |
| 2,629.00 | 3,914.00 | 2,799.00 | 3,958.00 | ||
Income Tax Provision |
300.00 | 833.00 | 291.00 | 842.00 | |
Income after Tax |
2,329.00 | 3,081.00 | 2,508.00 | 3,116.00 | |
Non-Controlling Interest |
3.00 | 1.00 | 1.00 | (1.00) | |
Net Income Common |
2,326.00 | 3,080.00 | 2,507.00 | 3,117.00 | |
EPS (Basic) |
1.50 | 1.99 | 1.61 | 2.02 | |
EPS (Diluted) |
1.48 | 1.97 | 1.61 | 2.00 | |
Shares (Basic, Weighted) |
1,549.00 | 1,549.00 | 1,551.00 | 1,551.00 | |
Shares (Diluted, Weighted) |
1,567.00 | 1,561.00 | 1,560.00 | 1,560.00 | |
Gross Margin |
79.89% | 82.48% | 83.60% | 81.82% | |
EBIT Margin |
19.21% | 27.77% | 20.57% | 27.07% | |
EBT margin |
16.96% | 25.60% | 18.19% | 24.42% | |
Net Profit Margin |
15.00% | 20.15% | 16.30% | 19.23% | |
EBITDA |
4,489.00 | 5,612.00 | 5,093.00 | 5,992.00 | |
EBIT |
2,978.00 | 4,246.00 | 3,164.00 | 4,387.00 | |
Income from Continuous Operations |
2,329.00 | 3,081.00 | 2,508.00 | 3,116.00 | |
Consolidated Net Income/Loss |
2,329.00 | 3,081.00 | 2,508.00 | 3,116.00 | |
EPS (Basic, from Continuous Ops) |
(1.80) | 1.99 | 1.62 | 2.01 | |
EPS (Diluted, from Cont. Ops) |
(1.79) | 1.97 | 1.61 | 2.00 | |
EPS (Basic, Consolidated) |
(1.80) | 1.99 | 1.62 | 2.01 | |
EPS (Diluted, Consolidated) |
(1.79) | 1.97 | 1.61 | 2.00 | |
Shares (Diluted, Average) |
1,563.00 | 1,561.00 | 1,560.00 | 1,560.00 | |
EBITDA Margin |
28.96% | 36.71% | 33.11% | 36.97% | |
Operating Cash Flow Margin |
15.11% | 21.97% | 18.62% | 28.79% |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026